| Home | Log Out | Upgrade | Our Services | My Account | Contact | Help |
|
|
|
||||||||
 |
 |
 |
 |  |
Notification of Transactions of Directors, Persons Discharging Managerial Responsibility or Connected Persons
I give below details of changes in the directors' interests in the Ordinary shares and American Depository Shares (ADSs) of GlaxoSmithKline plc.
On 31 December 2008, the Company's Non-Executive Directors were provisionally allocated the following awards over Ordinary shares and American Depository Shares (ADSs) in the Company through the annual reinvestment of dividends paid throughout 2008:
SmithKline Beecham Non-Executive Directors Retainer Fee and Share Allocation Award - Annual Dividend Reinvestment
|
Non-Executive Director |
No. of Ordinary Shares |
Average |
|
Sir Ian Prosser |
49.37 |
£12.58 |
GlaxoSmithKline Non-Executive Directors Automatic Share Award and Elected Share Award - Annual Dividend Reinvestment
|
Non-Executive Director |
No. of Ordinary Shares |
Average |
No. of |
Average Price ($) |
|
Sir Christopher Gent |
1,243.53 |
12.58 |
|
|
|
Prof Sir Roy Anderson |
37.59 |
12.58 |
|
|
|
Dr Stephanie Burns |
|
|
82.69 |
36.51 |
|
Mr Lawrence Culp |
|
|
727.54 |
36.51 |
|
Sir Crispin Davis |
1,103.24 |
12.58 |
|
|
|
Sir Deryck Maughan |
|
|
608.90 |
36.51 |
|
Dr Daniel Podolsky |
|
|
184.23 |
36.51 |
|
Sir Ian Prosser |
1,063.89 |
12.58 |
|
|
|
Dr Ronaldo Schmitz |
875.20 |
12.58 |
|
|
|
Mr Tom de Swaan |
102.19 |
12.58 |
|
|
|
Sir Robert Wilson |
304.09 |
12.58 |
|
|
The Company and the Non-Executive Directors were informed of these allocations on 5 January 2009.
This notification relates to transactions notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
S M Bicknell
Company Secretary
6 January 2009
 |
|
2006 MoneyAM© |